High Costs for Diagnosis, Care of Nonalcoholic Fatty Liver Disease

Share this content:
High Costs for Diagnosis, Care of Nonalcoholic Fatty Liver Disease
High Costs for Diagnosis, Care of Nonalcoholic Fatty Liver Disease

MONDAY, June 11, 2018 (HealthDay News) -- The health care costs associated with nonalcoholic fatty liver disease (NAFLD) are considerable, especially at first diagnosis, according to a study published online May 18 in Hepatology.

Alina M. Allen, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues examined the total health care cost and resource utilization associated with a new NAFLD diagnosis using U.S. medical and pharmacy claims data from OptumLabs Data Warehouse. A total of 152,064 adults with a first claim for NAFLD were identified, of whom 108,420 were matched to non-NAFLD contemporary controls in a 1:1 ratio. Participants were followed for a median of 2.6 years.

The researchers found that per NAFLD patient with private insurance, the total annual cost of care was $7,804 and $3,789 for a new diagnosis and for long-term management, respectively. These costs were significantly higher than the total annual costs per matched control with similar comorbidities ($2,298). The largest increases in health care utilization were represented by liver biopsies, imaging, and hospitalizations (relative risks, 55.0, 3.95, and 1.87, respectively), which may account for the increased costs in NAFLD versus controls.

"The costs associated with the care for NAFLD independent of its metabolic comorbidities are very high, especially at first diagnosis," the authors write. "Research efforts should focus on identification of underlying determinants of use, sources of excess cost, and development of cost-effective diagnostic tests."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »